Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 6Neoplasm Metastasis 2Stomach Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Ovarian Neoplasms 1Neoplasms 1Metastatic Castrate Resistant Prostate Cancer 1Liver Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 6Sorafenib 4Filgrastim 4Carboplatin 4Thiotepa 3Radiotherapy 3Psychiatric Rehabilitation 3Nivolumab 3Ipilimumab 3Cyclophosphamide 3sargramostim 2ixabepilone 2fludarabine 2Temozolomide 2Sirolimus 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Gene Expression Profiling 2Etoposide 2Drug Therapy 2Counseling 2Busulfan 2Bupropion 2Blood Specimen Collection 2Biopsy 2vofatamab 1utomilumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × tasquinimod × Genitourinary × Clear all
NCT01743469 2019-01-08

A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Ipsen

Phase 2 Completed
201 enrolled 23 charts
GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Liver Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡